Holen Sie sich die Stockscreener-App
0.4631
7.76%
-0.0291
Handel nachbörslich:
.47
0.0069
+1.49%
Athira Pharma Inc Aktie (ATHA) Neueste Nachrichten
What drives Athira Pharma Inc. stock priceHigh-yield capital appreciation - jammulinksnews.com
Is Athira Pharma Inc. a good long term investmentSuperior return velocity - Autocar Professional
Athira Pharma (NASDAQ:ATHA) Trading Up 8.4% – Here’s Why - Defense World
What analysts say about Athira Pharma Inc. stockFree Market Dynamics Reports - jammulinksnews.com
Investors Can Still File Late Claims in Athira Pharma Settlement — Here’s How to Get Your Share - TradingView
Lewy Body Dementia Market Set to Grow Substantially Through - openPR.com
Why Athira Pharma Inc. stock attracts strong analyst attentionHigh Accuracy Alerts - Newser
How Athira Pharma Inc. stock performs during market volatilityDouble Profit With Half Risk - Newser
What makes Athira Pharma Inc. stock price move sharplyTop Gaining Low Risk Assets - Newser
Athira Pharma (ATHA) Is Paying a $10M Settlement to Investors — Here’s How to Get Your Share - TradingView
Is Athira Pharma, Inc. technically bullish or bearish? - MarketsMojo
Two Sigma Advisers LP Has $149,000 Position in Athira Pharma, Inc. (NASDAQ:ATHA) - Defense World
ATHA LOSS ALERT: ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Athira Pharma, Inc. Investors with LARGE LOSSES to Secure Counsel Before Important Deadline in Securities Class Action – ATHA - ACCESS Newswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Athira Pharma (NASDAQ:ATHA) Trading 9.2% Higher – Here’s Why - Defense World
HAGENS BERMAN, NATIONAL ATTORNEYS, Alerts Athira Pharma (ATHA) Investors to Filing Of Securities Class Action, Advises Investors with Losses to Contact Firm's Attorneys Now - ACCESS Newswire
Athira Pharma Presents Data from ACT-AD Phase 2 Proof-of-Concept Clinical Study of Fosgonimeton in Mild-to-Moderate Alzheimer’s Patients at the Alzheimer's Association International Conference 2022 - Barchart.com
Athira Pharma Holds Annual Stockholders Meeting - TipRanks
Athira Pharma Presents Preclinical Data at the Alzheimer's Association International Conference 2022 - Barchart.com
This Athira Pharma Insider Increased Their Holding By 111% Last Year - Yahoo Finance
Athira Pharma’s SWOT analysis: als drug developer’s stock faces pivotal phase - Investing.com
Athira Pharma (ATHA) Highlights Promising Phase 1 Results for ALS Drug Candidate | ATHA Stock News - GuruFocus
Athira Pharma to present data from first-in-human Phase 1 trial of ATH-1105 - Yahoo Finance
Athira Pharma (ATHA) Projected to Post Earnings on Wednesday - Defense World
Athira Pharma Reports Reduced Losses and Strategic Focus - MSN
Athira Pharma to Present Data from First-in-Human Phase 1 Clinic - GuruFocus
Athira Pharma to Present Data from First-in-Human Phase 1 - GlobeNewswire
Breakthrough ALS Drug ATH-1105 Achieves Key Safety Milestones, Targets Patient Trials Late 2025 - Stock Titan
Athira Pharma Reports First Quarter 2025 Financial Results and P - GuruFocus
Athira Pharma Reports First Quarter 2025 Financial Results and Pipeline and Business Updates - The Manila Times
Athira Pharma, Inc. (NASDAQ:ATHA) Position Lowered by Renaissance Technologies LLC - Defense World
Athira Pharma Slides As Insider Purchases Lose Another US$89k - simplywall.st
Head-To-Head Review: NKGen Biotech (NYSE:NKGN) and Athira Pharma (NASDAQ:ATHA) - Defense World
Phenylketonuria Clinical Trial Pipeline Appears Robust With - GlobeNewswire
ATHAAthira Pharma, Inc. Latest Stock News & Market Updates - Stock Titan
Athira Pharma shifts to Nasdaq Capital Market amid compliance bid By Investing.com - Investing.com India
3.30%
1.54%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):